Amneal Pharmaceuticals, Inc. (AMRX) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001723128 · SEC filings checked Oct 18, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 30, 2026 | $796.2M | $57.7M | $0.18 | Filing |
| Mar 31, 2026 | Apr 22, 2026 | $722.5M | $62.3M | $0.19 | Filing |
| Dec 31, 2025 | Jan 13, 2026 | $814.3M | $35.1M | $0.10 | Filing |
| Sep 30, 2025 | Oct 30, 2025 | $784.5M | $2.4M | $0.01 | Filing |
| Jun 30, 2025 | Jul 21, 2025 | $724.5M | $22.4M | $0.07 | Filing |
| Mar 31, 2025 | May 2, 2025 | $695.4M | $12.2M | $0.04 | Filing |
| Dec 31, 2024 | Jan 15, 2025 | $730.5M | $-31.1M | $-0.10 | Filing |
| Sep 30, 2024 | Nov 8, 2024 | $702.5M | $-156,000 | $0.00 | Filing |
What would Amneal Pharmaceuticals, Inc. have to report for its valuation to change?
At $19.18, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 27.8% a year, to $1.64. On that path the next quarter needs diluted EPS near $0.01, against $0.01 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 27.8% | 27.8% |
| EPS needed in final year | $1.64 | $1.64 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. AMRX goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.